Correct Answer: B. Octreotide
After incomplete resection of a GH-secreting pituitary adenoma, medical management becomes essential. Octreotide is the first-line somatostatin analogue for acromegaly because it directly suppresses GH secretion via somatostatin receptor-2 (SSTR2) activation on somatotroph cells. Unlike GnRH agonists (leuprolide, nafarelin, goserelin), which target gonadotropins, octreotide acts on the somatotroph axis itself. The mechanism: somatostatin inhibits GH release through negative feedback at the hypothalamic-pituitary level. Octreotide has superior efficacy in reducing GH levels (60–70% of patients achieve GH <5 ng/mL) and normalizing IGF-1, the key marker of disease control. In Indian clinical practice, octreotide (both short-acting and long-acting depot formulations) is the DOC for residual/recurrent acromegaly post-surgery. It is preferred over dopamine agonists (bromocriptine) because GH-secreting adenomas are less dopamine-responsive. Long-acting octreotide (Sandostatin LAR 30 mg IM monthly) is used for maintenance in India, with rapid onset of action allowing symptom control while awaiting definitive radiotherapy or before repeat surgery.
Why the other options are wrong
A. Leuprolide — Leuprolide is a GnRH agonist that suppresses LH/FSH and is used for hypogonadism and prostate cancer, not acromegaly. It has no direct effect on somatotroph cells or GH secretion. NBE may trap students who confuse pituitary hormone suppression with GH suppression—leuprolide suppresses gonadotropins, not growth hormone. C. Nafarelin — Nafarelin is another GnRH agonist, similar to leuprolide, used for endometriosis and precocious puberty. It has no role in acromegaly management. The trap: students may recognize it as a pituitary-active agent and incorrectly assume it treats all pituitary hormone excess—it does not affect GH. D. Goserelin — Goserelin is a GnRH agonist (Zoladex) used for prostate cancer and endometriosis by suppressing gonadotropins. It does not suppress GH and is irrelevant in acromegaly. The NBE trap: grouping all GnRH agonists as 'pituitary suppressants' without distinguishing their specific hormone targets.
High-Yield Facts
- Octreotide is the first-line medical therapy for acromegaly (both primary and post-surgical residual disease) because it directly inhibits GH via somatostatin receptor-2 activation.
- GnRH agonists (leuprolide, nafarelin, goserelin) suppress gonadotropins (LH/FSH), not GH—they have no role in acromegaly.
- Somatostatin analogues (octreotide, lanreotide) achieve GH normalization in 60–70% of acromegaly patients; dopamine agonists are less effective because GH adenomas are dopamine-resistant.
- Long-acting octreotide (Sandostatin LAR) 30 mg IM monthly is the standard maintenance therapy in India for residual acromegaly post-incomplete surgery.
- IGF-1 normalization is the primary endpoint of acromegaly treatment; GH <5 ng/mL at rest is the biochemical target.
Mnemonics
SOMA for Acromegaly Somatostatin analogue (octreotide/lanreotide) → Opens SSTR2 → Mutes GH → Achieved IGF-1 control. Use when you see 'post-surgical acromegaly' or 'residual GH excess.' GnRH ≠ GH GnRH agonists (Leuprolide, Nafarelin, Goserelin) suppress Gonadotropins (LH/FSH), not Growth Hormone. Remember: GnRH is for sex hormones, not growth hormone.
NBE Trap
NBE pairs 'pituitary tumor' with 'hormone suppression' to lure students into choosing any GnRH agonist. The trap is forgetting that GnRH agonists only suppress gonadotropins—they do not affect somatotrophs or GH secretion. The discriminator is recognizing that acromegaly requires somatostatin analogues, not GnRH agonists.
Clinical Pearl
In Indian tertiary centers, octreotide is initiated immediately after incomplete GH adenoma resection to prevent disease progression while awaiting radiotherapy (which takes 6–12 weeks to show effect). Patients often report symptom relief (reduced sweating, joint pain) within days, improving quality of life during the treatment gap.
_Reference: KD Tripathi Pharmacology Ch. 31 (Endocrine Pharmacology); Harrison Ch. 375 (Acromegaly)_